Protein degradation 2.0? Third Rock sinks $56M into Cedilla's unusual approach
Third Rock Ventures is trotting out the latest player in the hot space of protein degradation, infusing the new startup with $56 million in launch money to find out if its unconventional approach to junking proteins works better than its rivals.
The upstart goes by Cedilla Therapeutics, and it’s entering a field of drug development that’s picking up a lot of steam this year. The concept behind the emerging space is simple enough: where protein inhibition has led to some advanced medicines, degrading proteins could prove a more fruitful solution. The approach could have major benefits over traditional small-molecule strategies, including the potential to cut down systemic drug exposure and the ability to tackle target proteins once considered undruggable.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.